Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06650808 in advanced solid tumors
NCT02129205Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jun 2014
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06650808 in solid tumor (advanced stage) and triple-negative breast cancer (TNBC), sponsored by Pfizer. Primary endpoints: Dose-limiting Toxicities and Objective Response Rate up to 3 years. Started Jun 2014; status: terminated.
02
Drugs
PF-06650808
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02129205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129205.